MOTS-c Research Overview

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial genome — an unusual origin that distinguishes it from nearly all previously characterized peptides. It was first identified in 2015 by Lee et al. at the University of Southern California and reported in Cell Metabolism, establishing it as a founding member of a growing class of bioactive sequences known as mitochondria-derived peptides (MDPs). This article provides an educational overview of peer-reviewed MOTS-c research for laboratory scientists and researchers.

All MOTS-c products supplied by New Tech Science are intended exclusively for in vitro and preclinical laboratory research. Nothing in this article constitutes medical advice or implies suitability for human or veterinary use.

Discovery and Mitochondrial Origin

MOTS-c is encoded within a small open reading frame in the mitochondrial 12S ribosomal RNA gene, a region previously considered non-coding. Its discovery expanded the recognized output of the mitochondrial genome and demonstrated that mitochondria produce peptides capable of acting as intercellular signaling molecules. MOTS-c belongs to the same MDP family as humanin and the small humanin-like peptides (SHLPs), all of which are encoded within mitochondrial ribosomal RNA genes and share stress-responsive expression patterns [13].

Metabolic Regulation and Insulin Sensitivity Research

The foundational 2015 discovery paper demonstrated that MOTS-c targets skeletal muscle cells and regulates metabolic homeostasis through a defined molecular pathway: MOTS-c inhibits the folate cycle, leading to intracellular accumulation of AICAR (an endogenous AMPK activator), which subsequently activates AMPK — a central energy-sensing kinase. In mouse models, MOTS-c treatment prevented both age-dependent and high-fat-diet-induced insulin resistance and obesity [1].

Subsequent animal research extended these findings to hormonal contexts. Using an ovariectomy mouse model of estrogen-deficiency-related metabolic dysfunction, a 2019 study found that MOTS-c activated brown adipose tissue thermogenesis, reduced white adipose accumulation, suppressed inflammatory signaling, and improved insulin sensitivity through AMPK-dependent mechanisms. Pharmacological AMPK inhibition attenuated these effects, confirming the pathway’s requirement [3].

Human observational data supports the relevance of endogenous MOTS-c to metabolic health. A 2018 case-control study found that circulating MOTS-c levels were significantly reduced in obese male children and adolescents compared to healthy controls, with inverse correlations to markers of insulin resistance (male-only cohort) [4]. A 2021 cross-sectional study in 125 non-diabetic adults found that android and liver fat positively associated with plasma MOTS-c levels, with the authors suggesting a possible compensatory hormetic response to metabolic burden [5], though circulating MOTS-c and adiposity associations vary across study cohorts.

Researchers interested in related metabolic signaling research may also find the GLP-1/GIP Pathway Research Overview and NAD+ Research Overview relevant.

Nuclear Translocation Under Metabolic Stress

A significant mechanistic finding emerged in a 2018 Cell Metabolism study demonstrating that MOTS-c is not confined to the cytoplasm under all conditions. Under metabolic stress, MOTS-c physically translocates from the cytoplasm to the nucleus via an AMPK-dependent mechanism, where it regulates nuclear genes containing antioxidant response elements and interacts with the transcription factor NRF2. The authors proposed that this represents a form of mitochondrial-nuclear co-regulation, with the mitochondrial genome independently encoding a factor that regulates nuclear gene expression [2].

Exercise Research

A 2021 study published in Nature Communications established MOTS-c as an exercise-induced mitokine in both animal and human contexts. MOTS-c administration enhanced physical performance in young, middle-aged, and old mice. Notably, late-life treatment initiated at 23.5 months of age (equivalent to approximately 70 human years) and continued three times per week significantly increased physical capacity and healthspan metrics in aged mice. In humans, aerobic exercise was shown to induce MOTS-c expression in skeletal muscle tissue and in circulating blood, establishing it as an endogenous exercise-responsive signal [6].

A 2022 human genetic study identified a naturally occurring MOTS-c variant (K14Q, common in East Asian populations) associated with higher fast-twitch muscle fiber proportions and greater leg strength. Among 1,594 athletes versus controls, sprint and power competitors showed significantly higher prevalence of the C allele (6.5%) compared to endurance athletes (2.9%), suggesting that MOTS-c genetic variation influences muscle phenotype [7].

Anti-Inflammatory Research

MOTS-c has been investigated for anti-inflammatory properties in animal models. A 2026 study using streptozotocin-induced diabetic rats found that MOTS-c treatment reduced fasting blood glucose and circulating C-reactive protein, while modulating plasma inflammatory cytokines and decreasing NLRP3 inflammasome activity in cardiac tissue — suggesting both systemic and organ-specific anti-inflammatory activity in the diabetic setting [8].

Cardiac Research

Two lines of cardiac research have examined MOTS-c. In an ex vivo rat heart model, MOTS-c treatment improved mechanical recovery from ischemia-reperfusion injury, reduced oxidative stress markers, preserved mitochondrial enzyme activity, and maintained mitochondrial DNA copy numbers across distinct mitochondrial subpopulations — outcomes attributed to the peptide’s capacity to preserve mitochondrial quality under ischemic stress [9].

A 2026 cross-sectional human study in 72 acute myocardial infarction patients found that postoperative peripheral MOTS-c levels were significantly lower in patients who developed myocardial ischemia-reperfusion injury compared to those who did not. Multivariate analysis identified MOTS-c as an independent protective factor against this complication, raising interest in its potential as a clinical biomarker [10]. This is observational data and does not establish a causal protective role.

Bone Research

Two animal-model studies have examined MOTS-c in bone biology. A 2016 study in ovariectomized mice found that daily MOTS-c treatment over 12 weeks significantly reduced bone loss as confirmed by micro-CT, operating through AMPK-dependent suppression of osteoclast differentiation via RANKL signaling [11]. A 2018 in vitro study using rat bone marrow mesenchymal stem cells identified a complementary bone-protective mechanism: MOTS-c promoted osteogenic differentiation through TGF-β/Smad pathway activation, with knockdown of TGF-β1 reversing the effect [12].

Current Research Status

A comprehensive 2023 review in the Journal of Translational Medicine summarized the current state of MOTS-c research: the folate-AICAR-AMPK pathway represents the primary characterized mechanism; MOTS-c expression responds to exercise and metabolic stress; and evidence spans energy metabolism, insulin sensitivity, inflammation, and age-related biology across animal and observational human studies [14]. A concurrent 2023 review noted that while plasma MOTS-c levels decline with age and therapeutic applications appear promising across multiple disease models, no effective clinical application method has yet been established [15].

As of the current literature, no human clinical trials have tested MOTS-c as an investigational intervention. All human data is observational or genetic-association in nature. MOTS-c is not approved by the U.S. Food and Drug Administration or any comparable regulatory agency for human therapeutic use.

Researchers interested in related mitochondria-focused peptide research may also find the SS-31 Research Overview relevant.

Research Use Note

MOTS-c is supplied by New Tech Science exclusively for in vitro and preclinical laboratory research applications. Products undergo third-party purity verification to support research-grade standards. This article is provided for educational purposes only and does not constitute medical advice. Researchers should consult current peer-reviewed literature and their institutional ethics framework before working with this compound.

References

1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443–454. https://doi.org/10.1016/j.cmet.2015.02.009 (PMID 25738459)
2. Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metabolism. 2018;28(3):516–524. https://doi.org/10.1016/j.cmet.2018.06.008 (PMID 29983246)
3. Lu H, Wei M, Zhai Y, et al. MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction. Journal of Molecular Medicine. 2019;97(4):473–485. https://doi.org/10.1007/s00109-018-01738-w (PMID 30725119)
4. Du C, Zhang C, Wu W, et al. Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance. Pediatric Diabetes. 2018;19(6):1058–1064. https://doi.org/10.1111/pedi.12685 (PMID 29691953)
5. Sequeira IR, Woodhead JST, Chan A, et al. Plasma mitochondrial derived peptides MOTS-c and SHLP2 positively associate with android and liver fat in people without diabetes. Biochimica et Biophysica Acta – General Subjects. 2021;1865(12):129991. https://doi.org/10.1016/j.bbagen.2021.129991 (PMID 34419510)
6. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12(1):470. https://doi.org/10.1038/s41467-020-20790-0 (PMID 33473109)
7. Kumagai H, Natsume T, Kim SJ, et al. The MOTS-c K14Q polymorphism in the mtDNA is associated with muscle fiber composition and muscular performance. Biochimica et Biophysica Acta – General Subjects. 2022;1866(1):130048. https://doi.org/10.1016/j.bbagen.2021.130048 (PMID 34728329)
8. Mills AR, de Souza A, Pham T, Mugisho OO. Mitochondrial peptide MOTS-c suppresses systemic and cardiac inflammasome activation in a diabetic rat model. Experimental Physiology. 2026. https://doi.org/10.1113/EP093714 (PMID 42321010)
9. Santhanam SS, Jayaraman S, Rajesh SS, Harihara Iyer VN, Kurian GA. MOTS-c preserves mitochondrial subpopulation bioenergetics and genome integrity to attenuate cardiac ischemia reperfusion injury. Molecular Biology Reports. 2026. https://doi.org/10.1007/s11033-026-12064-7 (PMID 42228044)
10. Peng L, Li Y, Duan X, et al. The Association Between Serum MOTS-c Levels and Myocardial Ischemia-Reperfusion Injury in Patients with Acute Myocardial Infarction. Biomedicines. 2026;14(4):918. https://doi.org/10.3390/biomedicines14040918 (PMID 42072458)
11. Ming W, Lu G, Xin S, et al. Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation. Biochemical and Biophysical Research Communications. 2016;476(4):412–419. https://doi.org/10.1016/j.bbrc.2016.05.135 (PMID 27237975)
12. Hu BT, Chen WZ. MOTS-c improves osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells via TGF-beta/Smad pathway. European Review for Medical and Pharmacological Sciences. 2018;22(23):8516–8522. https://doi.org/10.26355/eurrev_201811_16247 (PMID 30468456)
13. Lee C, Kim KH, Cohen P. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radical Biology and Medicine. 2016;100:182–187. https://doi.org/10.1016/j.freeradbiomed.2016.05.015 (PMID 27216708)
14. Wan W, Zhang L, Lin Y, et al. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. Journal of Translational Medicine. 2023;21(1):36. https://doi.org/10.1186/s12967-023-03885-2 (PMID 36670507)
15. Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in Endocrinology. 2023;14:1120533. https://doi.org/10.3389/fendo.2023.1120533 (PMID 36761202)